EE04152B1 - 2-(R)-1-(R)-(3,5-bis(trifluorometüül)fenüül)etoksü)-3-(S)-(4-fluoro)fenüül-4-(3-(5-oks o-1H,4H-1,2,4-triasolo)metüülmorfoliini polümorfne vorm, meetod selle valmistamiseks ja seda sisaldav farmatseuti line kompositsioon - Google Patents

2-(R)-1-(R)-(3,5-bis(trifluorometüül)fenüül)etoksü)-3-(S)-(4-fluoro)fenüül-4-(3-(5-oks o-1H,4H-1,2,4-triasolo)metüülmorfoliini polümorfne vorm, meetod selle valmistamiseks ja seda sisaldav farmatseuti line kompositsioon

Info

Publication number
EE04152B1
EE04152B1 EEP199900603A EEP9900603A EE04152B1 EE 04152 B1 EE04152 B1 EE 04152B1 EE P199900603 A EEP199900603 A EE P199900603A EE P9900603 A EEP9900603 A EE P9900603A EE 04152 B1 EE04152 B1 EE 04152B1
Authority
EE
Estonia
Prior art keywords
phenyl
triazolo
methylmorpholine
oxo
trifluoromethyl
Prior art date
Application number
EEP199900603A
Other languages
English (en)
Estonian (et)
Inventor
S. Crocker Louis
A. Mccauley James
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800216.5A external-priority patent/GB9800216D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of EE9900603A publication Critical patent/EE9900603A/xx
Publication of EE04152B1 publication Critical patent/EE04152B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polyamides (AREA)
  • Polyurethanes Or Polyureas (AREA)
EEP199900603A 1997-07-02 1998-07-01 2-(R)-1-(R)-(3,5-bis(trifluorometüül)fenüül)etoksü)-3-(S)-(4-fluoro)fenüül-4-(3-(5-oks o-1H,4H-1,2,4-triasolo)metüülmorfoliini polümorfne vorm, meetod selle valmistamiseks ja seda sisaldav farmatseuti line kompositsioon EE04152B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5160097P 1997-07-02 1997-07-02
GBGB9800216.5A GB9800216D0 (en) 1998-01-07 1998-01-07 Polymorphic form of a tachykinin receptor antagonist
PCT/US1998/013766 WO1999001444A1 (en) 1997-07-02 1998-07-01 Polymorphic form of the tachykinin receptor antagonist 2-(r)-(1-(r) -(3,5-bis(trifluoromethyl) phenyl)ethoxy)-3-(s)-(4-fluoro) phenyl-4-(3-5 (-oxo-1h,4h-1,2,4,-triazolo) methylmorpholine

Publications (2)

Publication Number Publication Date
EE9900603A EE9900603A (et) 2000-08-15
EE04152B1 true EE04152B1 (et) 2003-10-15

Family

ID=26312895

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900603A EE04152B1 (et) 1997-07-02 1998-07-01 2-(R)-1-(R)-(3,5-bis(trifluorometüül)fenüül)etoksü)-3-(S)-(4-fluoro)fenüül-4-(3-(5-oks o-1H,4H-1,2,4-triasolo)metüülmorfoliini polümorfne vorm, meetod selle valmistamiseks ja seda sisaldav farmatseuti line kompositsioon

Country Status (27)

Country Link
EP (1) EP0994867B1 (xx)
JP (1) JP2000513383A (xx)
KR (1) KR20010020593A (xx)
CN (1) CN1106390C (xx)
AT (1) ATE372991T1 (xx)
AU (1) AU735230B2 (xx)
BG (1) BG64703B1 (xx)
CA (1) CA2293836C (xx)
CZ (1) CZ295410B6 (xx)
DE (1) DE69838421D1 (xx)
DZ (1) DZ2551A1 (xx)
EA (1) EA002405B1 (xx)
EE (1) EE04152B1 (xx)
HK (1) HK1029345A1 (xx)
HR (1) HRP980370B1 (xx)
HU (1) HU228003B1 (xx)
ID (1) ID23191A (xx)
IL (1) IL133357A (xx)
IS (1) IS2617B (xx)
NO (1) NO316893B1 (xx)
NZ (1) NZ501589A (xx)
PE (1) PE86499A1 (xx)
PL (1) PL191496B1 (xx)
SK (1) SK285644B6 (xx)
TR (1) TR199903299T2 (xx)
TW (1) TW577887B (xx)
WO (1) WO1999001444A1 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1228068A1 (en) * 1999-10-29 2002-08-07 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
EP1509524B1 (en) * 2002-05-31 2008-03-26 Schering Corporation Xanthine phosphodiesterase v inhibitor polymorphs
GB0417702D0 (en) * 2004-08-09 2004-09-08 Merck Sharp & Dohme New uses
US8080656B2 (en) 2005-10-05 2011-12-20 Ranbaxy Laboratories Limited Process for the preparation of aprepitant
KR20080089659A (ko) 2006-02-03 2008-10-07 그렌마크 파머수티칼스 엘티디. 아프레피탄트의 비정질 및 결정 형태 및 그것의 제조 방법
SG10201500027TA (en) 2006-04-05 2015-02-27 Opko Health Inc Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
WO2008026216A2 (en) * 2006-08-28 2008-03-06 Hetero Drugs Limited Process for purification of aprepitant
WO2008044102A1 (en) * 2006-10-13 2008-04-17 Glenmark Pharmaceuticals Limited Polymorph form of aprepitant and process for the preparation thereof
EP2129381A1 (en) 2007-01-24 2009-12-09 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
PT2254579T (pt) * 2008-02-18 2018-04-16 Esteve Labor Dr Utilização de compostos que se ligam aos ligandos de recetor sigma para o tratamento de dor neuropática que se desenvolve como uma consequência de quimioterapia
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
PT2727912T (pt) * 2011-06-30 2017-07-25 Toray Industries Cristais de derivado de glicina e seu uso farmacêutico
CN103030668B (zh) * 2011-10-09 2016-06-15 江苏豪森药业集团有限公司 一种制备福沙匹坦二甲葡胺的方法
CZ304770B6 (cs) 2012-03-13 2014-10-08 Zentiva, K.S. Způsob výroby 3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluormethyl)fenyl)ethoxy)-3-(4-fluorfenyl)morfolino)methyl)-1H-1,2,4-triazol-5(4H)-onu (Aprepitantu) v polymorfní formě II
CN102850339B (zh) * 2012-10-17 2014-10-15 上海博志研新药物技术有限公司 一种神经激肽(nk-1)受体拮抗剂晶型制备方法
CN103288813A (zh) * 2013-06-04 2013-09-11 四川百利药业有限责任公司 一种阿瑞匹坦的制备方法
KR20160097366A (ko) 2013-12-17 2016-08-17 라보라토리오스 델 드라. 에스테브.에스.에이. 세로토닌-노르에피네프린 재흡수 억제제들(SNRIs) 및 시그마 리셉터 리간드들 조합
CN104119325B (zh) * 2014-07-15 2017-03-22 中山奕安泰医药科技有限公司 阿瑞吡坦多晶型物的制备方法
CN105837526B (zh) * 2016-01-22 2018-02-27 浙江工业大学 一种阿瑞吡坦重要合成中间体(2s,3r)‑4‑苄基‑3‑(4‑氟苯基)吗啉‑2‑醇的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
NO996549L (no) 2000-03-01
HK1029345A1 (en) 2001-03-30
SK285644B6 (sk) 2007-05-03
HRP980370B1 (en) 2002-10-31
CZ477799A3 (cs) 2000-09-13
CA2293836C (en) 2007-06-05
IS5293A (is) 1999-12-10
ATE372991T1 (de) 2007-09-15
EA199901114A1 (ru) 2000-08-28
KR20010020593A (ko) 2001-03-15
BG104010A (en) 2001-08-31
PE86499A1 (es) 1999-10-25
EE9900603A (et) 2000-08-15
TR199903299T2 (xx) 2000-07-21
AU8283398A (en) 1999-01-25
TW577887B (en) 2004-03-01
BG64703B1 (bg) 2005-12-30
EP0994867A1 (en) 2000-04-26
IL133357A0 (en) 2001-04-30
HRP980370A2 (en) 1999-04-30
HUP0004008A3 (en) 2002-03-28
JP2000513383A (ja) 2000-10-10
CN1261882A (zh) 2000-08-02
NO316893B1 (no) 2004-06-14
HU228003B1 (en) 2012-08-28
EA002405B1 (ru) 2002-04-25
ID23191A (id) 2000-03-23
EP0994867B1 (en) 2007-09-12
CZ295410B6 (cs) 2005-08-17
WO1999001444A1 (en) 1999-01-14
PL191496B1 (pl) 2006-05-31
CN1106390C (zh) 2003-04-23
IL133357A (en) 2003-12-10
AU735230B2 (en) 2001-07-05
DE69838421D1 (en) 2007-10-25
CA2293836A1 (en) 1999-01-14
DZ2551A1 (fr) 2003-08-15
IS2617B (is) 2010-04-15
HUP0004008A2 (hu) 2002-02-28
NO996549D0 (no) 1999-12-29
PL337579A1 (en) 2000-08-28
SK187299A3 (en) 2000-07-11
NZ501589A (en) 2001-10-26

Similar Documents

Publication Publication Date Title
EE04152B1 (et) 2-(R)-1-(R)-(3,5-bis(trifluorometüül)fenüül)etoksü)-3-(S)-(4-fluoro)fenüül-4-(3-(5-oks o-1H,4H-1,2,4-triasolo)metüülmorfoliini polümorfne vorm, meetod selle valmistamiseks ja seda sisaldav farmatseuti line kompositsioon
ZA985765B (en) Polymorphic form of a tachykinin receptor antagonist.
MY155911A (en) Pharmaceutical composition of a tachykinin receptor antagonist
UY24472A1 (es) Composiciones de agonistas/antagonistas de estrógenos y agonistas/antagonistas de prostaglandinas, útiles en el tratamiento de la osteoporosis
FI942381A (fi) Aryylisubstituoituja heterosyklisiä yhdisteitä
HUP0400491A2 (hu) Eljárás (2R,2-alfa-R,3A)-2-[1-[3,5-bisz(trifluormetil)fenil]-etoxi-3-(4-fluorfenil)-1,4-oxazin előállítására
NO20045001L (no) Fremgangsmate for fremstilling av 5-[[2(R)-[1(R)-[3,5-bis(trifluormetyl)fenyl]etoksy]-3(S)-(4-fluorfenyl)-4-morfolinyl]metyl]-1,2-dihydro-3H-1,2,4-triazol-3-on
WO2002034699A3 (en) Mammalian metabolites of a tachykinin receptor antagonist
AR026288A1 (es) Forma polimorfica de un antagonista del receptor de taquicinina
MY126509A (en) Polymorphic form of a tachykinin receptor antagonist
TH72742B (th) องค์ประกอบทางเภสัชกรรมของสารต้านตัวรับแทคคีไคนิน
BR9810360A (pt) Forma polimórfica do composto 2-(r)-(1-(r) - (3,5-bis(tri-fluorometil)fenil)etoxi) -3-(s) - (4-fluoro) fenil-4(3- (5-oxo-1h,4h-1,2,4-triazolo) metilmorfolino, processo para preparação da forma 1 do mesmo, composição farmacêutica, processo para antagonizar o efeito da substância p em seu sìtio receptor ou para o bloqueio dos receptores da neurocinina-1 em um mamìfero, processos para tratar ou prevenir uma condição selecionada, a êmese, um distúrbio do sistema nervoso central, a depressão, a ansiedade, e esquizofrenia em um mamìfero, e produto
ECSP003740A (es) Forma polimorfica de un antagonista de receptor de taquiquinina
TH77074A (th) องค์ประกอบทางเภสัชกรรมของสารต้านตัวรับแทคคีไคนิน
ECSP982575A (es) Forma polimorfica de un antagonista de receptor de taquiquinina
TH47996A (th) รูปแบบโพลีมอร์ฟิกของยาต้านฤทธิ์ตัวรับของแทกกีคินิน
TH17690B (th) รูปแบบโพลีมอร์ฟิกของยาต้านฤทธิ์ตัวรับของแทกกีคินิน

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name